Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jessica Merrill

Senior Editor

New York, NY
Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest From Jessica Merrill

With Vertex Pain Drug Filed At FDA, Commercial Ramp Is Under Way

The company initiated a rolling NDA submission for suzetrigine for acute pain, positioning the drug for a launch in 2025.

Commercial Launches

Pfizer Recruits Industry Analyst Baum To Advance Corporate Strategy

Longtime pharmaceutical industry analyst Andrew Baum will join Pfizer’s executive leadership team.

Leadership Companies

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

The US Food and Drug Administration has requested additional efficacy information on the supplemental filing in the potentially large new indication.

Immune Disorders Inflammation

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Pfizer’s management team addressed topics ranging from COVID-19 revenues to Medicare’s drug negotiation program and new product launches.

Sales & Earnings Coronavirus COVID-19

Ono Buys Deciphera, Gaining A Commercial Cancer Drug And Infrastructure

The Japanese pharmaceutical company will acquire Deciphera for $2.4bn, gaining GIST treatment Qinlock (ripretinib).

Cancer M & A

Merck Investors Keeping A Close Watch On Winrevair Uptake

Some patients have already been prescribed the new drug for pulmonary arterial hypertension but Merck & Co. did not provide any sales or guidance. 

Sales & Earnings Launches
See All
UsernamePublicRestriction

Register